Litcius/Paper detail

Anticancer Drug-Induced Capillary Leak Syndrome

Hassan Izzedine, Alexis Mathian, Zahir Amoura, Jia Hwei Ng, Kenar D. Jhaveri

2022Kidney International Reports36 citationsDOIOpen Access PDF

Abstract

The term capillary leak syndrome (CLS) describes the manifestations associated with an increased capillary permeability to proteins leading to an escape of plasma from the blood circulatory system to surrounding tissues, muscle, organs, or body cavities. This results clinically in the typical triad of hypotension, edema, and elevated hematocrit. The more severe cases of CLS may present with cardiovascular collapse, shock, and death. The most classic form of this pathology is represented by the idiopathic systemic CLS (SCLS) also called Clarkson's disease, but capillary leaks are also described as adverse drug reactions foremost among which are anticancer drugs. This review will focus on oncologic drugs such as gemcitabine, therapeutic growth factors or cytokines, and monoclonal antibodies (mAbs) that appear now as the strongest candidates for anticancer drug-induced CLS.

Topics & Concepts

MedicineVascular permeabilityCLs upper limitsEdemaDrugShock (circulatory)HematocritLeakGemcitabinePathologyInternal medicinePharmacologyChemotherapyEnvironmental engineeringEngineeringOptometryMuscle and Compartmental DisordersChemotherapy-induced cardiotoxicity and mitigationNeuroblastoma Research and Treatments
Anticancer Drug-Induced Capillary Leak Syndrome | Litcius